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A b s t r a c t  
The purpose of this study was to design a chitosan matrix systems made with cross-linking agents 
that targets control release of anticancer drug. Chitosan (CS) with cross-linking agent sodium sulfate 
(SS) was used for entrapping the model drug Doxorubicin Hydrochloride (DOX) through novel gel 
casting method. Scanning Electron Microscopy (SEM), Fourier Transforms Infrared Spectroscopy 
(FTIR), X-ray Diffraction (XRD), swelling index, drug entrapment efficiency and in vitro drug release 
studies were also done for physicochemical characterization of the formulations. Statistically 
significant different t50% and MDT values were noted between SS (5% w/v), SS (10% w/v) matrix 
systems and the control, as well as between SS (5% w/v) matrix systems and all the other 
formulations at pH 5.8 and pH 7.4. DOX release was slower in matrix systems without Explotab® 
and also at higher dissolution media pH (7.4). Statistically significant dissimilarity was observed 
between the control and the SS (5% w/v) f2 = 11.32μ2.54; SS (10% w/v) f2 = 12.16μ0.82 at pH 7.4. 
The findings of the study suggested that the matrix formulation is a promising carrier for DOX 
delivery. 
Keywords: Chitosan, Sodium Sulfate, Cross-linking Agents, Gel Casting Method, Drug Delivery. 
Introduction 
Typically, hydrophilic polymer matrix systems are swells on contact 
with water to form a hydrated matrix layer [1, 2]. This outer 
hydrated matrix layer erodes, as it becomes more dilute. The rate 
of erosion depends on the nature of the polymer [3-8]. Drugs that 
are dispersed in a matrix formed by soluble polymer molecules rely 
on slow swelling and dissolution of the matrix to give continuous 
release of the drug. A true gel is a matrix system where 
interactions between the polymer chains are more than just 
random hydrogen bonds [9]. The cross-link between polymer 
chains in such a gel can either be chemical bonds or physical 
bonds, which limit mobility of the polymer chains and give a rigid 
structure to the gel. Matrix drug delivery systems can also be 
referred to as wafers or matrices discs, biscuits or cookies etc [10-
13]. 
For release of modifiers and lubricant/glidants requires a 
combination of suitable hydrophilic colloid along with drug in 
hydrophilic polymer matrix systems. Distribution of drug during 
hydrated matrix is limited step for drug release [14-16].  There are 
two universal types of true gels hydrophilic matrix systems which 
are formed either chemical (covalent) or physical bonds (helix 
formation based on hydrogen bonds or ionic interactions) by the 
cross-linked polymeric structures. Hence, chitosan is one of the 
exceptional polymeric viscous matrices easy entanglements of 
adjoining polymer chains [10]. The use of chitosan in the 
development of drug delivery preparations is based on studies with 
chitosan intra-gastric tablets and chitosanăcoated drug delivery 
systems [17, 18]. Drugs dispersed in chitosan were released at a 
constant rate, thus highlighting its potential as a sustained-release 
matrix polymer [19, 20].  
To the best of our knowledge, no study has been reported on 
chitosan matrix systems made with sodium sulfate cross-linking 
agents using gel casting method. Here, we present the drug 
release properties of cross link chitosan matrix systems. The aim of 
this study is to investigate the cross-linking ability and the influence 
of the type of cross-linking agent on the drug release properties of 
chitosan matrix systems prepared by a unique gel casting method.  
Physicochemical characterization of the formulations has been 
done by in vitro drug swelling index study. Schematically 
presentation of DOX release from cross link chitosan matrix 
System was shown in Figure. 1. 
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Figure 1: Schematically Presentation of DOX Release from Cross Link Chitosan Matrix System. 
Materials and Methods 
Materials 
Chitosan (75% deacetylated), sodium sulfate, acetic acid, 
Explotab® and doxorubicin Hydrochloride were purchased from 
Sigma Aldrich, India. The other entire reagent used was of 
analytical grade. 
Preparation of Chitosan Cross-link Matrix with Loaded 
Doxorubicin 
Chitosan solution was prepared by dissolving 3g of chitosan in 
100ml of 2% (v/v) acetic acid solution at 60oC with continuous 
stirring for 30 minutes. After complete dissolution of the CS, DOX 
was dispersed into CS solution using a high-speed rotary mixer. 
This mixer was run at 800rpm for 10 minutes followed by at 
1000rpm for 20 minutes at 30˚C. Then accurately measured 
quantities of the cross-linking agent sodium sulfate with different 
concentrations (5% and 10%) were dissolved in distilled water. The 
sodium sulfate of these two different concentrations were added 
separately to the chitosan-DOX suspension to cross-link the 
chitosan over a period of 1 hour to form true gels under continuous 
stirring with a magnet stirrer at 30˚ĈC. Another batch of these 
formulations was prepared with the addition of a disintegrant, 
Explotab®, at a concentration of 3% w/v shown in Table-1. The 
gels were dried in a drying oven for 60 minutes at 37˚C and further 
forced through a 2mm sieve while still damp to obtain granules. 
Equal aliquots of the cross-linked chitosan wet granular gels were 
loaded using a spatula into the moulding compartments of 24-well 
polystyrene plates. The moulding frames containing cross-linked 
matrix systems were dried in a drying oven at 37˚ĈC for another 48 
hours. The dry matrix systems that were formed inside the 
moulding frames were removed and stored in light and moisture 
protected containers. 
 
Table -1: Composition of the Samples: 
Formulation code CS 
(w/v %) 
SS 
( %w/v) 
Explotab® DOX 
mg/ml 
F1 3 5 - 2 
F2 3 10 - 2 
F3 3 5 3 2 
F4 3 10 3 2 
Drug Content in Chitosan Matrix System 
Exactly 500mg powder of crushes matrix systems was taken and 
then stirred for 24 hours in 100ml of 0.1M NaOH. The solution 
which was ultrasonicated for 15minutes then filtered. From this 
solution, 5ml of sample was taken to find out the amount of DOX 
present in the sample by UV-vis Spectroscopy.  Both concentration 
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and quantity of DOX was calculated by using the equation of 
standard curve. 
Methods 
Physical Properties of the Chitosan Matrix Systems 
(Weight Variation, Hardness) 
Total 20 matrix systems of each formulation were calculated for 
weight variation to evaluate conformity with standard specifications 
for solid dosage forms. Twenty matrix systems were arbitrarily 
choosen and weighed one at a time and their standard weight was 
determined.  For each formulation, the hardness of 20 randomly 
selected matrix systems was examined using a hardness tester 
(Erweka, Germany). Each matrix system was subjected to an 
increasing compressional force and the value at which the mobile 
jaw of the hardness tester started to bounce back was recorded as 
the tensile strength on recoil (hardness) of the matrix system. 
Scanning Electron Microscopy (SEM) 
The surface morphology of the chitosan matrix was examined 
using scanning electron microscopy (Jeol Datum Ltd., G5/IL/42/08. 
Tokyo, Japan). Samples were deposited on stub using one side of 
a double-sided adhesive dried carbon tape (NEM Tape, Nisshin 
Em. Co. Ltd., Tokyo, Japan). The working distance 25mm was 
maintained and acceleration voltage used was 17 kV with 
secondary electro image (SEI) as a detector. 
Fourier Transforms Infrared Spectroscopy (FT-IR) 
Fourier Transform Infrared Spectrum of pure DOX, chitosan, 
sodium sulfate, SSăCS physical mixture and drug loaded matrix 
were recorded in range of 4000ă400 cm_1 using FT-IR (Perkin 
Elmer) from KBr pellet to find out the drug excipient compatibility 
study. 
X-ray diffraction Analysis (XRD) 
This study is useful to investigate crystallinity of the drug in cross-
linked matrix. It was performed with X-ray diffractometer (ULTIMA-
III, Rigaku, Japan), using nickel filtered Cu Ka radiation (a voltage 
of 40 kV and a current of 30 mA) for pure drug and formulated 
matrix. 
Swelling Studies 
The swelling ratios of three matrix systems were determined of 
each formulation [21]. Then, it was weighed and kept in a glass 
beaker containing 500ml of phosphate buffer at pH 5.8 μ 0.1 and 
pH 7.4 μ 0.1 respectively at 37˚C with continuous stirring at 50rpm. 
After that, every one hour intervals removed matrix systems from 
buffer, maximum of 8 hours and then taken weight by removing 
excess surface moisture using blotting paper. The variation of dry 
weight and swollen state was calculated on the basis of the degree 
of swelling (Swt). 
ܵ௪௧ ൌ
௦ܹ െ ௗܹ
ௗܹ
ܺ 100 
Where: Ws = Weight of Swollen Matrix Systems. 
Wd = Weight of Dry Matrix Systems. 
Friability Studies 
The matrix systems were weighed together and then put in a 
friabilator (Erweka, Germany) [22]. The apparatus was run at 
25rpm for 4minutes, i.e. rotated 100 rotations, according to the 
United States Pharmacopoeia (USP) 23, (1995:1981). After 100 
rotations, the matrix systems were removed, dusted and their total 
weight determined. The percentage friability was calculated. 
ܨ ൌ ଵܹ
െ ଶܹ
ଶܹ
ܺ 100 
 
Where: W1 = Initial Weight of Twenty Matrix Systems. 
W2 = Weight of Twenty Matrix Systems after the Friability Test. 
In vitro Drug Release Studies 
Phosphate buffers of pH 5.8 μ 0.1 and 7.4 μ 0.1 were prepared 
according to the method of the USP 23 (1995:2049-2050). The 
experimental conditions for the dissolution tests were as follows: 
Dissolution volume = 900 ml, Rotation speed = 60 rpm, Sample 
intervals = 0, 15 minutes to 24 hours; Temperature = 370C, and 
Sample volume = 5 ml. The amount of DOX released was 
analyzed using a UV spectrophotometer at the λ max value of 234 
nm [23]. 
Analysis of Dissolution Data 
Dissolution experiments on the different matrix system formulations 
and the control were performed in triplicate on a fully calibrated 
eight station dissolution auto sampling apparatus using the paddle 
method (USP Apparatus II, Electro lab TDT 08L, India).  Statistical 
analysis of the data was performed on the calculated t50% values 
and mean dissolution times (MDT) using a one-way repeated 
analysis of variance (ANOVA) with Microsoft Excel® (Microsoft 
Corporation, Redmond, WA, USA) to calculate the p-values. The 
differences between the values (both t50% and MDT) of the 
experimental groups were considered statistically significant if p ª 
0.05. 
Results and Discussion 
Physical Properties of the Chitosan Matrix  
The average weights, hardness and friability of the different matrix 
systems are given in Table - 2. The matrix systems prepared from 
5% w/v SS had higher hardness   values than those made from the 
10% w/v SS formulation. Matrix formation and physical bonding 
between the chitosan chains and the anionic cross-linking agents 
depend therefore on both the type of cross-linking agent and its 
concentration. An optimum concentration clearly exists for SS in 
terms of the hardness of the matrix systems and increasing the 
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concentration of SS results in a decrease in the hardness. Addition 
of Explotab® to the cross-linked chitosan formulations resulted in 
an increase, although relatively small, in the hardness of the matrix 
systems as compared to those without Explotab®. This may be 
explained by a contribution of the Explotab® molecules to the 
cross linking of the cationic chitosan chains in the matrix systems. 
This probable higher density of cross-linking resulted in matrix 
systems with increased hardness. The matrix systems showed a 
decrease in friability with the addition of Explotab®, which is in 
accordance with the physical strength of the matrices as observed 
during the hardness tests and swelling experiments.  
 
Table -2: Physical Properties and Drug Content of the Chitosan Cross-link Matrix System. 
F.C No Weight (mg) Hardness (N) P.I μ SD Friability (%) Drug content: mg/0.5 
g unit 
F1 505.090 μ .765 54.20 μ 12.5 0.160μ .027 1.23 124.708μ1.981
F2 498.090 μ .453 49.34 μ 5.72 0.140μ .023 0.47 93.363 μ 1.706
F3 501.090 μ .843 57.12 μ 8.65 0.160μ .026 1.08 104.591 μ0.780
F4 478.090 μ .385 52.63 μ 2.76 0.140μ .022 0.43 97.554μ2.106
 
SEM (Scanning Electron Microscopy) 
In Figure. 2, the SEM of original F1, F2, F3 and F4 are 
demonstrated. The cross sections of the matrix systems it is clear 
that the morphology changed with the use of different types of 
cross-linking agents [24, 25]. Addition of Explotab® influenced the 
structure of the matrices; the presence of the Explotab® seems to 
cause bigger crevices and pores to form in the internal structure of 
the matrix systems. These pores may contribute to a faster rate of 
fluid penetrating the matrices with a subsequent faster dissolution 
of the incorporated drug. 
 
 
2F1 
 
Parida et. al. International Journal of Drug Delivery 7 (2) 101-112 [2015] 
 
 
  
PAGE | 105 |
 
 
2F2 
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2F4 
Figure 2: SEM of Cross Link Chitosan Matrix System. 
 
 
FTIR (Fourier Transforms Infrared Spectroscopy) 
FTIR analysis was performed to characterize any chemical 
changes that occurred during the preparation of cross-link chitosan 
matrix. Figure. 3 shows the FTIR spectra of CS, CS-SS. It shows 
N-H stretching at 3500-3200 as well N-H bends at 1550-1450 nm 
in the primary amine functional group. It was observed that the 
symmetric stretching for SO4 at 1123nm as well as asymmetric 
bending of SO4 at 615nm in Sodium sulfate. Here, it was observed 
that in case of chitosan sulfate, the two peaks could match up in 
the regions of 615nm and 1100nm due to presence of sulfate. On 
the other hand, the shifting of 1513nm of the amino group bends 
into higher wave number which may signify a higher energy level 
for cross-linked chitosan sulfates. This was confirmed that the 
bending of the N-H group could limit in sulfate anion by chemical 
interaction. The shifting of the N-H deformation band to higher 
frequencies in hydrogen bonding which was already been reported 
earlier. This shift was implied due to the occurrence of cross-linking 
reaction among sulfate anions and ammonium groups of chitosan 
[26].  
 
Figure 3: FTIR of Cross Link Chitosan with Sodium Sulfate Matrix System. 
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XRD (X-ray diffraction) Analysis 
The cross link chitosan matrix was used for x-ray diffraction 
analysis. The diffracted intensities were recorded from 5 to 80Ĉ at 
2θ angles. The diffraction pattern in Figure. 4 corresponds to CS, 
F1, F2, F3 and F4 were studied. The X-ray diffraction of the raw 
CS shows two characteristic peaks at around 2θ=11.281 and at 
2θ=21.181. After being prepared into cross-link with sodium 
sulfate, the CS shows two similar diffraction peaks but with 
decreased intensity. This is due to that part of the crystallized CS 
may transfer into amorphous state during the phase parathion 
process. When Explotab® was added to the chitosan cross-link 
matrix solution, irrespective of amount, the peaks with decreased 
intensity remained at the same position indicating that the 
formation of intercalation and exfoliated hybrids.
 
Figure 4: XRD of Cross Link Chitosan Matrix System. 
Drug Content of the Matrix Systems 
A plot of absorbance versus the concentration of DOX (mg/100 ml) 
in 0.1 M NaOH at 234 nm is shown in Figure. 5. This standard 
curve of DOX was obtained by the spectrophotometrical 
determination of the absorbencies of the serial dilutions performed. 
The r2 value of the curve was found to be equal to unit (i.e. perfect 
straight line). This implies a 100% confidence interval in predicting 
the value of the concentration corresponding to any extrapolated 
absorbance value along the curve. The DOX content values 
(mg/0.5 g of product mass) of the different matrix systems are 
shown in Table -2. The DOX content of the different types of matrix 
systems ranged from 93.3mg/0.5g to 124.7mg/0.5g, which 
represents 15 to 25% of the product weight. The variation in drug 
content between the different types of matrix systems may be 
attributed to the uneven loss of DOX during the cross-linking phase 
of matrix preparation into the supernatant. 
 
Figure 5: DOX Standard Curve. 
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Swelling Properties at 5.8 and 7.4 
Evaluation of the swelling properties of the chitosan cross link 
matrix systems F1, F2, F3 and F4 at pH 5.8 and 7.4 in Figure. 6a 
and 6b. In pH 5.8, the F1 formulation showed a swelling ratio of 
75% within 2 hours. SS is a highly reactive surfactant, which 
means it has a tendency to enhance fluid penetration and wetting 
of the matrix systems. Addition of Explotab® to F3 formulation 
increased the swelling ratios to values close to 225%, which 
represent a 150% increase in the swelling ratio of the matrix 
systems without Explotab®. The matrix systems F2 reached a 
swelling ratio of about 100% within three hours and then 
disintegrated. This sudden disintegration suggests a quick 
reversing of the bonds after a hydration time of three hours. 
Addition of Explotab® to F4 formulation, however, changed the 
swelling properties of the matrix systems in such a way that 
relatively high swelling ratios of between 125 to 175% were 
reached. Additionally, the matrix systems containing Explotab® did 
not disintegrate during the total period of the swelling test. This is in 
accordance with the hardness results that showed an increase in 
strength with addition of Explotab®. 
In Figure. 6b, the F1 formulation showed a swelling ratio of 83% 
within 2 hours compared to the 75% at pH 5.8. On addition of 
Explotab® to F3 formulation, the swelling ratio increased to values 
close to 225%, which represents an increase of 125% as 
compared to the formulation without Explotab®. The swelling 
curves for the F1and F3 matrix systems that incorporated 
Explotab® at pH 5.8 and pH 7.4 resembled each other closely as 
depicted in Fig. 6a and 6b, respectively. 
The F3 formulation swelled to a ratio of about 100% within 1 hour, 
but slowly started to erode and eventually disintegrated after 5 
hours. This indicated an influence of pH on the swelling properties 
and reversibility of the bonds between the cross-linked chitosan 
molecules, which lead to disintegration of the matrix. Furthermore, 
addition of Explotab® to the F4 formulation influenced the swelling 
properties of the matrix systems, attaining swelling ratios between 
125 to 175%. From the results of the swelling experiments, it is 
clear that the Explotab® increased the physical strength of the 
matrix systems to such an extent that they remained intact 
throughout the 8 hour swelling test. 
The relatively high increase in the swelling ratio of the matrix 
systems during the first hour may be indicative of a possible high 
drug release rate over the initial period after administration. The 
drug release properties are discussed under the results of the 
dissolution tests. Swelling ratios were lower than those at pH 5.8, 
suggesting probably slower drug release rates at pH 7.4. 
 
 
Figure 6a: Variation in the Swelling Ratio with time (hours) for the different Chitosan Matrix Systems at pH 5.8. 
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Figure 6b: Variation in the Swelling Ratio with time (hours) for the different Chitosan Matrix Systems at pH 7.4. 
 
Drug Release Studies at pH5.8 and pH 7.4 
The cumulative percentages of DOX obtained from the in vitro drug 
release experiments at pH 5.8 and 7.4 are depicted in Figure. 7a 
and 7b. In pH5.8, the release of DOX from the matrix systems F1 
increased gradually from values as low as 30% in the first hour to a 
maximum percentage of approximately 81% in 8 hours. In case of 
the matrix F2 the matrix systems released about 77% of their DOX 
load in 8 hours, F3 and F4 systems that contained Explotab® 
accomplished a maximum release value of approximately 80% and 
94% respectively by the end of the test. 
Although inclusion of Explotab® in the cross-linked chitosan matrix 
systems did not cause disintegration of the delivery systems that is 
a known effect in the case of compressed tablets, it managed to 
increase the drug release rate. Therefore, this disintegrates 
exhibited ideal properties by increasing the hardness, swelling 
characteristics and drug release rate of the matrices without 
affecting their integrity. 
In pH7.4, on the contrary, drug release from the matrix systems of 
chitosan cross-linked with F1 and F2 respectively, showed slower 
rates compared to that of the control, and their respective 
formulations at pH 5.8. The cross-linked chitosan matrix systems 
released between 64-69% of their DOX within eight hours. On 
addition of Explotab®, the amount of DOX released increased to 
between 80-85%. Therefore, it was postulated that the pH of the 
dissolution media affects the rate of drug release from a cross-
linked chitosan formulation [27]. This can be explained by the 
possible higher protonation of the free amino groups (i.e. those not 
involved in the cross-links) on the chitosan molecules at pH 5.8 as 
well as those involved in the cross-links, which might influence the 
reversibility of the ionic cross-links. At a neutral pH, the protonation 
of the amino groups occurs to a lower extent with a consequent 
lower extent of cross-links reversed that results in a slower drug 
release rate [28, 29]. 
 
Figure 7a: Cumulative % DOX released versus time (minutes) at pH 5.8. 
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Figure 7b: Cumulative % DOX released versus time (minutes) at pH 7.4. 
Analysis of Dissolution Data 
In vitro dissolution experiments were statistically analyzed using 
the techniques described under analysis of results in Table - 3. 
Complete sets of values of the t50%, MDT, and the similarity factor 
(f1) as well as the difference factor (f2) for all the different matrix 
systems at pH 5.8 and pH 7.4 in triplicates are presented. A high 
MDT value indicates a slow rate of drug release and a lower MDT 
value means the rate of DOX release was higher.  The mean 
values (μ standard deviations) for the t50% (n=3), the fit factors {f1, 
f2 (n=3)} at pH 5.8 and pH 7.4 respectively, and their 
corresponding standard deviations. The following criteria were 
adapted in the determination and the interpretation of f1 and f2 
values: f1 < 15 and f2 > 50 for profiles that were statistically 
significantly not similar to the control up to an end point equal to six 
intervals corresponding to 120 minutes. Not more than one point 
with a cumulative % DOX value higher than 85% should be 
considered as this could yield an f2 value above 100. 
 
Table 3: Statistical Analysis for the Dissolution Data at pH 5.8 and pH 7.4 
F.C 
Code 
pH5.8 pH7.4 
*t50% (min) f1 #f2 *t50% (min) f1 #f2 
F1 136.3 μ 10.3 83.32 μ 7.11 16.11 μ 3.37 199.2 μ 80.0 94.60 μ 12.20 11.32 μ 2.54 
F2 130.0 μ 25.0 80.06 μ 5.91 17.02 μ 2.51 162.7 μ1 5.5 91.00 μ 1.01 12.16 μ 0.82 
F3 102.5 μ 2.5 84.40 μ 2.57 16.25 μ 1.95 55.3 μ 21.6 70.77 μ 5.47 17.70 μ 0.91 
F4 31.2 μ 3.2 50.84 μ 11.12 27.11 μ 3.58 35.3 μ 9.6 57.43 μ 0.45 21.97 μ 1.00 
 
Conclusion 
From the above research the higher protonation of amino groups at 
a lower pH value (5.8) with reversing of the cross-link and faster 
release of the incorporated drug was observed. Addition of 
Explotab® to the matrix systems significantly reduced their t50% 
thus indicating a faster release of the drug. This was expected as 
Explotab® increases the swelling properties of the matrices and 
showed a more porous structure. Based on the MDT values and 
the fit factors f1 and f2, it was concluded that the anionic surfactant 
SS are good cross-linking agents for chitosan. Matrix systems 
formed with these cross-linking agents released the drug 
significantly slower as compared to an immediate release dosage 
form. The effect of Explotab® and a lower dissolution medium pH 
on the release of DOX from the different chitosan matrix systems 
was increased the rate of drug release from the chitosan matrix 
systems. 
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